Ten63 Therapeutics
Ten63 Therapeutics designs novel, durable therapeutics for hard-to-drug cancer targets by combining physics-based chemistry with AI-driven design. The company is a venture-backed drug discovery platform that uses generative quantum chemistry and accelerated quantum simulations (Astrolabe) alongside machine learning models for ADMET prediction and multi-parameter optimization to generate and prioritize candidates. Their proprietary BEYOND/COPPER platform explores large chemical spaces to target proteins like Myc, KRas G12D, and DDR1/2 and to anticipate resistance mechanisms. Ten63 works with biotech and pharmaceutical partners to advance molecules toward development. The approach targets high unmet need in oncology by enabling discovery against targets previously considered undruggable.
Ten63 Therapeutics
Ten63 Therapeutics designs novel, durable therapeutics for hard-to-drug cancer targets by combining physics-based chemistry with AI-driven design. The company is a venture-backed drug discovery platform that uses generative quantum chemistry and accelerated quantum simulations (Astrolabe) alongside machine learning models for ADMET prediction and multi-parameter optimization to generate and prioritize candidates. Their proprietary BEYOND/COPPER platform explores large chemical spaces to target proteins like Myc, KRas G12D, and DDR1/2 and to anticipate resistance mechanisms. Ten63 works with biotech and pharmaceutical partners to advance molecules toward development. The approach targets high unmet need in oncology by enabling discovery against targets previously considered undruggable.
TL;DR
Focus: AI- and physics-driven drug discovery for hard-to-drug oncology targets
Proprietary platform: BEYOND/COPPER using generative quantum chemistry and accelerated quantum simulations
Founded / HQ: Founded 2018; headquarters Durham, United States
Team size (approx.): 27 employees
Recent financing: Series A announced Dec 19, 2024
Company Overview
Problem Domain
Oncology; discovering therapeutics for hard-to-drug or previously undruggable protein targets (examples cited: Myc, KRas G12D, DDR1/2).
Founded
2018
Industry
Biotechnology
Tech Stack
Funding Track Record
Reported seed round
Reported seed round
Reported Series A
Series A announced Dec 19, 2024
Investor Signal
“Participation from SOSV (IndieBio), Hatteras Venture Partners, Draper Associates, Alexandria Venture Investments, Sigma Group, Morpheus Ventures”